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Abstract
Growth factors are in clinical use to stimulate bone growth and regeneration. BMP-2 is used in long
bone and spinal surgery, PDGFbb for the treatment of periodontal defects and children with
growth hormone receptor deficiency are treated with IGF-I.
Aim of the present study was the comparative analysis of the effect of these growth factors released
from a local drug delivery system on cells of the osteogenic lineage at differing differentiation stages.
The experiments with the mesenchymal cell line C2C12 revealed a proliferating effect of all three
growth factors and a differentiating effect of BMP-2 with a dramatic increase in alkaline phosphatase
activity. None of the growth factors stimulated cell migration.
Human osteoblast like cells showed similar results with an increase in proliferation after stimulation
with IGF-I or PDGFbb. The enzymatic activity of alkaline phosphatase was enhanced only in the
cells stimulated with BMP-2. This group showed also more mineralized matrix compared to the
other groups.
In conclusion, the growth factors IGF-I and PDGFbb delivered with a local drug delivery system
stimulated cell proliferation, whereas BMP-2 showed a dramatic effect on differentiation on
osteoblast precursor cells and osteoblast like cells.
Background
Today BMPs are used in spine and orthopaedic surgery,
the platelet derived growth factor (PDGFbb) for perio-
dontal treatment [1] and insulin growth factor-I (IGF-I) to
treat children with growth hormone insensitivity syn-
drome or IGF-I deficiency [2,3]. These three growth fac-
tors belong to different families and initiate their
signaling from the cell surface by different receptors and
intracellular pathways. The IGF and PDGF signals are
transduced via tyrosine kinases [4,5] and the BMP signal
via serine/threonine kinase [6,7]. Several in vitro and pre
clinical in vivo studies have been performed to demon-
strate the effect of the growth factors on different cell types
and bone [8-13].
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For the clinical use of growth factors the delivery system is
important [14]. Once a growth factor reaches the site of
action, it must remain at the site in an appropriate con-
centration and long enough for the pharmacological
effect. The half life of growth factors in vivo is very short
and they are metabolized within a few hours [15]. For the
use in bone regeneration, however, an action over a longer
time period is necessary. For a therapeutical success these
requirements must be met and therefore an adequate car-
rier must be used for drug delivery. A drug delivery system
based on poly(D,L-lactide) (PDLLA) was developed for
local release [16]. In previous studies the release profile of
the growth factors incorporated in the PDLLA coating by
eluting in PBS or cell culture medium was investigated.
The incorporated growth factors were released with an ini-
tial peak with in the first 2 to 3 days. The peak release is
followed by a slow sustained release [16,17]. Storage of
the coated implants over 14 month had no effect on the
activity of the incorporated growth factors on osteoblast
like cells [17]. The PDLLA serves as a coating for ortho-
pedic implants with incorporated pharmacological
agents. Using this application system, aim of the study
was the comparison of BMP-2, IGF-I and PDGFbb in their
effect on different cell types. Primary human osteoblast
like cells were used to investigate the effect of the growth
factors on bone forming cells. The used cell line C2C12
differentiates rapidly into myoblasts after reaching conflu-
ence [18]. This cell line has also the potential to differen-
tiate to adipocytes [19] or osteoblast like cells [18] and
therefore serve as a model for pluripotent mesenchymal
cells. The potential of these cells to differentiate into the
osteoblastic linage is used to test the osteoinductivity of
bone grafting materials [20]. Using the C2C12 cells the
osteoinductivity and migratory effect of the growth factors
was analyzed.
Methods
Cell culture
Osteoblast like cells were isolated from tibia plateau after
reconstructive surgery with the permission of the local
authorities. An informed consent was obtained from all
donors. For isolation of the cells, the trabecular bone was
minced into little pieces followed by overnight digestion
with collagenase Type II according to established proto-
cols [21] 1 × 105 osteoblasts were cultivated in 12 well
plates in DMEM/F-12-media with 10% heat inactivated
FCS at 37°C and 5% CO2. After cultivation of the cells for
3 days under identical conditions, the implants were
added to the culture in a non-contact manner using a tis-
sue culture inserts (0.4 µm pore size, Nunc, Germany).
The cells were cultured for further 15 days. One third of
the medium was changed every day to ensure only gentle
changes in the medium composition and growth factor
concentration.
Three parallel test series were performed with pooled cells
from different donors. Each test series was done in tripli-
cate.
The mice myoblast cell line C2C12 (ACC 565) was
obtained from DSMZ, Braunschweig, Germany. 5 × 104
cells were cultivated in 24 well plates in DMEM with 10%
heat inactivated FCS at 37°C and 5% CO2. After a 5 h
adherence period medium was changed to DMEM with
only 1% heat inactivated FCS to reduce the proliferation
activity. The implants were placed into the culture wells
and the cells were cultured for three days. The test were
conducted in triplicate and repeated two times.
Growth factors
The growth factors were applied to the cell culture from a
local drug delivery system. The drug delivery system is
based on a Poly(D,L-lactide)-coating (Boehringer, Ingel-
heim, Germany) on Titanium Kirschner-wires (1.0 mm
diameter, Synthes USA) and described in more detail else-
where [16].
Three different recombinant human growth factors were
used for the experiments:
IGF-I (R&D-Systems, Wiesbaden, Germany), BMP-2
(Osteogenetics, Würzburg, Germany) and PDGFbb (Bio-
mimetics, Franklin, USA).
According to previous experiments [11,12] the growth fac-
tors were incorporated in 5% (w/w) in the PDLLA coating.
The amount of growth factor added to the cell cultures
was 15 µg/ml (osteoblast) and 10 µg/ml (C2C12).
The difference in the applied growth factor amount (15
µg/ml or 10 µg/ml) is due to the different cell culture
approaches (24 well plates or 12 well plates) used and the
fact that the factors were applied from coated titanium k-
wires. For control served k-wires coated with the carrier
PDLLA.
Analysis
Cell vitality and proliferation was achieved via a non inva-
sive/toxic cell activity assay (alamarBlue, Assay, Biozol,
Eching, Germany). For the assay, 10% alamarBlue was
added to the cells and incubated for 3 h at 37°C. The
absorbance was measured in triplicate spectrophotometri-
cal with a micro plate reader at two wavelengths: 570 and
600 nm in accordance to the instruction of the manufac-
turer.
The catalytic activity of the alkaline phosphatase (AP) was
determined using para-nitrophenyl phosphate (p-NPP,
Sigma, Germany) as a substrate of the enzyme. After rins-
ing the cells the freshly prepared AP-buffer was added andJournal of Orthopaedic Surgery and Research 2007, 2:27 http://www.josr-online.com/content/2/1/27
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incubated for 30 min at 37°C. The absorbance was read
out in triplicate on a micro plate reader by 405 nm wave-
length.
The Osteocalcin concentration was quantified with an
ELISA (Metra Osteocalcin EIA kit, Quidel, San Diego, CA).
De Novo synthesis of collagen type-I was quantified to
detect carboxyterminal propeptide of type I collagen
(CICP, Quidel, San Diego, CA), a decomposition product
of collagen type-I. Supernatant from the cell cultures was
used and both ELISA were performed in accordance to the
instructions of the manufacturer.
Matrix mineralization was evaluated by the use of Von
Kossa stain. Cells were rinsed and fixed with cool metha-
nol for 10 min. After rinsing with water cells were incu-
bated for 30 min at room temperature (RT) with 3% silver
nitrate and for 2 min in formaldehyde. Surplus silver
nitrate was removed by incubation in 5% sodium thiosul-
fate for 5 min at RT.
Migration assay was performed by using a well established
assay [22]. Briefly, the growth factor coated wires were
placed to the lower chamber of polycarbonate-mem-
brane-inserts (8 µm pore size, Nunc, Germany) and cov-
ered with DMEM with 0.1% BSA. After 24 h 5 × 104
pluripotent mesenchymal cells (C2C12) were added to
the upper chamber and cultured under standard condi-
tions. For positive control, 10% FCS was added to the
lower chamber. After 5 h of incubation, the membrane
was removed and the cells on the surface carefully
abscised. Cells migrated into the membrane were fixed
with 4% w/v paraformaldehyd (PFA, Sigma, Germany),
stained with 4',6-Diamidino-2-phenylindole (DAPI,
Sigma, Germany) and counted under the microscope.
Statistical analysis
In order to compare the data of the independent test seri-
als, the results of the experimental groups were normal-
ized to the results of the PDLLA-group (control).
Statistical differences were assessed using an ANOVA and
Dunnett Post Hoc test was employed for multiple com-
parison tests at a level of 95% (Software SPSS12.0).
Results
Osteoblast like cells
The results of the growth factor groups and the different
assays were normalized to the PDLLA group which was set
100%. This method was chosen for accounting for differ-
ences between the serials. All cell cultures were started
with a comparable cell number (day 0, Fig. 1a). Over the
experimental period of 10 days a significant increase in
cell number was detectable in the PDGFbb and IGF-I
group compared to the PDLLA group (Fig. 1a). No effect
of BMP-2 on cell proliferation was detectable. The enzy-
matic activity of alkaline phosphatase, however, was sig-
nificantly higher in the BMP-2 treated osteoblast like cells
at days 10 and 15 (Fig. 1b). The two other growth factors
had no influence on the AP-activity. The von Kossa stain
for mineralized extra cellular matrix after 15 days revealed
a clear stimulating effect of BMP-2 on the mineralization
(Fig. 2a–d). No effect on collagen-1 and osteocalcin syn-
thesis was observed after treatment with growth factors
(data not shown).
C2C12 cell line
All three growth factors, PDGFbb, IGF-I and BMP-2, stim-
ulated significantly the cell proliferation in the myoblast
cell line (Fig. 3a). The effect of BMP-2, however, was less
pronounced. The alkaline phosphatase activity was only
significantly increased after stimulation with BMP-2 com-
pared to the PDLLA group (Fig. 3b). This is also clearly vis-
ible in the alkaline phosphatase stain in Figure 2e–h.
In the standard cell culture wells, the pluripotent mesen-
chymal cell line showed an accumulation around IGF-I
coated k-wire (Fig. 2g). This effect was not seen for
PDGFbb or BMP-2.
The migration assays (Boyden Chamber) revealed a signif-
icant migratory effect of the positive control (FCS) on the
cells. None of the growth factors, however, showed an
effect on the migratory activity of the pluripotent mesen-
chymal cell line (Fig. 3c).
Discussion
The biological stimulation of bone regeneration is a grow-
ing field. Several growth factors necessary for bone devel-
opment, maintenance, and regeneration have been
identified. This study aims to compare the effectiveness of
three growth factors approved for clinical use released
from a local drug delivery system: PDGFbb, IGF-I and
BMP-2. Two different cell types were used to investigate
the effect of the different growth factors. In both cell types,
primary human osteoblast like cells and a murine
pluripotent mesenchymal cell line, BMP-2 induced cell
differentiation, whereas IGF-I and PDGFbb stimulated
cell proliferation. None of the investigated growth factors
induced migration in the Boydan chamber assay.
The pluripotent myoblast cell line is a well established
system for testing osteoinductivity by using the reversible
potential of the cells to differentiate into osteoblastic phe-
notype after stimulation with osteoinductive factors [18].
The observed effect of BMP-2 on pluripotent mesenchy-
mal cell line is in accordance with previous studies show-
ing the osteoinductivity of this growth factor [23,24]. The
performed Boyden Chamber experiment showed no
migratory effect of the used growth factors on the C2C12Journal of Orthopaedic Surgery and Research 2007, 2:27 http://www.josr-online.com/content/2/1/27
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cells and this is in accordance with a study by Allen at al.
[22]. The proliferating effect was the strongest in the
myoblast culture treated with IGF-I followed by PDGFbb
and then BMP-2.
The mitogenic effect of the growth factors IGF-I and
PDGFbb released from the implant coating on osteoblast
like cells and pluripotent mesenchymal cells is also in
accordance with previous studies [8,25,26]. The prolifer-
ating effect of the growth factors seem to be differentia-
tion depending, because BMP-2 stimulated proliferation
only in the pluripotent cell line, whereas no effect was
shown on the osteoblast like cells.
The results concerning the effect of both factors (PDGFbb
and IGF-I) on osteoblast differentiation are controversy.
a) Cell count of the osteoblast like cell culture treated with different growth factors Figure 1
a) Cell count of the osteoblast like cell culture treated with different growth factors. The data presented are normalized to the 
control group (PDLLA) which is set 100%. A significant increase in the cell number was seen after treatment with PDGFbb or 
IGF-I (days 2–10) in comparison to the PDLLA treated cells (ANOVA, Dunnett). b) Alkaline phosphatase activity (AP) of the 
osteoblast like cell culture treated with different growth factors. The data presented are normalized to the control group 
(PDLLA) which is set 100%. A significant increase in AP activity was seen after treatment with BMP-2 (days 5–15) in compari-
son to the PDLLA treated cells (ANOVA, Dunnett).Journal of Orthopaedic Surgery and Research 2007, 2:27 http://www.josr-online.com/content/2/1/27
Page 5 of 8
(page number not for citation purposes)
Some studies demonstrated an enhanced collagen and
osteocalcin synthesis [8,27,28], other studies, however,
found no effect [25,29]. The present study showed also no
effect on the activity of alkaline phosphatase, the colla-
gen-1 synthesis and the osteocalcin level in the medium.
The stimulating effect of BMP-2 on alkaline phosphatase
activity of osteoblast like cells has been reported earlier
[30,31]. The stimulating effect of BMP-2 on osteocalcin
expression as described by Spinella-Jaegle et al. was not
seen in the present study [32]. This might be due to the
different cells used in the experiments. Spinella-Jaegle per-
formed the experiments with the murine preosteoblastic
cell line MC3T3 and in the present study primary human
osteoblast like cells were used.
In vivo studies on bone healing revealed an expression of
the three analyzed growth factors at different healing
phases. Cho and coworkers used a mouse fracture model
and found BMP-2 expression only at the first day after
fracture indicating the role in the very early healing phase
[33]. The quantification of IGF-I during rat fracture heal-
ing on the protein level revealed no increase in the early
phase in comparison to the unfractured tibia. In the phase
corresponding to the chondrogenesis and intramem-
braneaus ossification (days 10, and 15) a significant
increase of IGF-I was detectable [34]. The immunohisto-
chemical detection of PDGF during mice fracture healing
showed that PDGF is expressed by several cell types during
almost the entire healing period [35].
The different phases of fracture healing are characterized
by the presents of different cell types [36,37]. In addition,
the receptors on the cells also vary depending on the dif-
ferentiation stage of the cell [38,39]. These data point out
that the three investigated factors are important during
different healing phases. The controlled temporal regula-
tion of growth factor action is necessary because of the
interaction of the different factors. Less information on
the interaction of factors is available, but the study by
Cirri et al. demonstrated the inhibition of PDGF induced
cell proliferation after application of insulin [26]. The
simultaneous application of IGF-I, TGF-β1 and PDGF to
osteoblast like cells enhanced the in vitro bone formation
synergistically [40]. Therefore, for optimal stimulation of
bone repair the controlled and local delivery of factors
and factor combinations is mandatory [14,41,42]. In the
present study the growth factors were delivered by using a
local drug delivery system. Further studies are now neces-
sary to identify the most potent stimulating factors and
the timing of delivery. Based on the implant coating for
local drug delivery we will develop a sequential drug
a-d) hOB 15 days after culturing with different growth factors stained with a combination of AP (blue) and v. Kossa Figure 2
a-d) hOB 15 days after culturing with different growth factors stained with a combination of AP (blue) and v. Kossa. An intense 
mineralization is detectable in the osteoblast like cells treated with BMP-2 (d). e-h) C2C12 cells stained for alkaline phos-
phatase. The pluripotent mesenchymal cell line treated with BMP-2 (h) showed an intense blue alkaline phosphatase staining.Journal of Orthopaedic Surgery and Research 2007, 2:27 http://www.josr-online.com/content/2/1/27
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release system for the temporally optimized delivery of
stimulating factors.
Conclusion
In conclusion, the growth factors IGF-I and PDGFbb
delivered with a local drug delivery system stimulated cell
proliferation, whereas BMP-2 showed a dramatic effect on
differentiation in osteoblast precursor cells and osteoblast
like cells.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BW conceived, supervised, coordinated the study, per-
formed the statistical analysis and wrote the manuscript.
NB carried out the experiments with the C2C12 cells ML
carried out the experiments with the osteoblast like cells.
TV and GS participated in the study design and coordina-
tion and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We thank BioMimetic Therapeutics, Inc., USA, for providing the PDGFbb.
The authors gratefully acknowledge the support of the German Research 
Foundation (KFO 102/2-1, TP 11).
a) Cell count of the pluripotent mesenchymal cell line (C2C12) treated with different growth factors Figure 3
a) Cell count of the pluripotent mesenchymal cell line (C2C12) treated with different growth factors. The data presented are 
normalized to the control group (PDLLA) which is set 100%. A significant increase in the cell number was seen after treatment 
with PDGFbb, IGF-I or BMP-2 in comparison to the PDLLA treated cells (ANOVA, Dunnett). b) Alkaline phosphatase activity 
(AP) of pluripotent mesenchymal cell line (C2C12) treated with different growth factors. The data presented are normalized to 
the control group (PDLLA) which is set 100%. A significant increase in AP activity was seen after treatment with BMP-2 in 
comparison to the PDLLA treated cells (ANOVA, Dunnett). c) Migration assay of C2C12 cells. A significant migration was 
detectable in the control group (10% FCS) but not in the growth factor groups.Journal of Orthopaedic Surgery and Research 2007, 2:27 http://www.josr-online.com/content/2/1/27
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